Jimmy Lin

Jimmy Lin is the President & CEO at Rare Genomics Institute and a former Chief Scientific Officer (CSO), Oncology at Natera. Jimmy has also worked as part of the ClinOmics: Intramural Clinical Genomics Program at the National Cancer Institute (NCI) / National Institutes of Health (NIH) and as part of the Advisory Panel on Patient Engagement at the Patient-Centered Outcomes Research Institute ( PCORI ).

Lin has dedicated their career to developing non-invasive methods for analyzing DNA and improving the diagnosis and management of genetic disease. Their work has helped transform the field of cancer detection and treatment, and they continue to be a leading voice in the fight against this disease.

Jimmy Lin started their educational career by attending Yale University where they studied Cognitive Science, Molecular Biochemistry & Biophysics. Jimmy then attended The Johns Hopkins University School of Medicine where they obtained their MD/PhD (MSTP) in Cellular and Molecular Medicine. After that, they attended Johns Hopkins Bloomberg School of Public Health where they obtained their Master's Health Sciences in Bioinformatics. Lastly, they are currently attending Reformed Theological Seminary to obtain their MAR in Thesis: Systematic Theology of Medicine.

Some direct reports include Romina Ortiz - Chief Operating Officer, Imran Babar - Chief Scientific Officer, and Anita Chacko - VP, Patient Research Services.